Witryna7 mar 2024 · The author also highlights the findings from the IMPOWER 010 phase III study of atezolizumab versus best supportive care following adjuvant chemotherapy for resected NSCLC. Furthermore, the author provides an overview of ongoing phase III studies testing adjuvant immune checkpoint inhibitors. Witryna23 mar 2024 · Mar 23, 2024. Nichole Tucker. An update from the phase 3 IMpower010 study shows that the study has met its primary end point of improvement in disease …
IMpower010 - Slideset Download - Clinical Oncology 2024 CCO
Witryna8 sie 2024 · An interim analysis of overall survival data from the IMpower010 trial showed an overall survival trend in favor of atezolizumab in the PD-L1 TC > 1% stage … Witryna8 sie 2024 · IMpower010 Trial Highlights Trend Towards OS Benefit With Atezolizumab in Resected NSCLC Aug 8, 2024 Hayley Virgil Conference IASLC World Conference … global number for microsoft
IMpower010 Shows Significantly Improved Disease-free Survival
Witryna25 maj 2024 · At the interim analysis, IMpower110 met its primary OS endpoint, with a statistically significant and clinically meaningful improvement for atezo vs chemo in … Witryna8 cze 2024 · In a planned interim analysis of IMpower010, adjuvant atezolizumab improved DFS in patients with PD-L1-positive, stage II-IIIA, fully resected NSCLC. Greater effects were observed in patients with high PD-L1 expression, while PD-L1-negative patients received no benefit from atezolizumab treatment. In the randomized … Witryna1293P - IMpower150: Updated efficacy analysis in patients with EGFR mutations. Date 17 Sep 2024. Session E-Poster Display. Topics Tumour Site Non-Small Cell Lung Cancer . Presenters Martin Reck. Citation. Annals of Oncology (2024) 31 (suppl_4): S754-S840. 10.1016/annonc/annonc283 ... global nursing staffing agency